Previous Article | Next Article 
J Virol, June 1998, p. 5231-5238, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Similar Levels of Human Immunodeficiency Virus Type
1 Replication in Human TH1 and TH2
Clones
Judy A.
Mikovits,1
Dennis D.
Taub,2
Susan M.
Turcovski-Corrales,2 and
Francis W.
Ruscetti3,*
Intramural Research Support Program,
SAIC-Frederick,1 and the Laboratory of
Leukocyte Biology,3 National Cancer
Institute-Frederick Cancer Research and Development Center, Frederick,
Maryland, and
Immunology Program, National Institute of Aging,
Baltimore, Maryland2
 |
ABSTRACT |
Studies on the development and function of CD4+
TH1 and TH2 cells during the progression to
AIDS may increase the understanding of AIDS pathogenesis. The
preferential replication of human immunodeficiency virus (HIV) in
either TH1 or TH2 cells could alter the
delicate balance of the immune response. TH1 (gamma
interferon [IFN-
] positive, interleukin-4 [IL-4] and IL-5
negative) and TH2 (IFN-
negative, IL-4 and IL-5
positive) clones, developed from several healthy donors, pedigreed by
reverse transcriptase PCR (RT-PCR) and enzyme linked immunosorbent
assay have similar levels of cell surface expression of CD4 and several
chemokine receptor cofactors necessary for viral entry. After
activation by specific antigens and infection with T-cell-tropic
strains of HIV type 1 (HIV-1), TH1 and TH2
clones showed similar levels of viral entry and reverse transcription.
At days 3 through 14 postinfection, HIV replicated to similar levels in
several TH1 and TH2 clones as measured by release of HIV p24 and total number of copies of gag
RNA/total cell RNA as measured by RT-PCR. When values were normalized
for viable cell number in three clones of each type, there was up to
twofold more HIV RNA in TH1 than TH2 cells. In
addition, several primary monocytotropic HIV-1 strains were able to
replicate to similar levels in TH1 and TH2
cells. These studies suggest that the importance of TH1 and
TH2 subsets in AIDS pathogenesis transcends clonal
differences in their ability to support HIV replication.
 |
INTRODUCTION |
During AIDS progression,
CD4+ T cells are severely reduced first in biological
responsiveness and then in cell numbers, leading to a degeneration of
the patient's ability to generate an effective immune response
(22, 40). The propagation of human immunodeficiency virus
(HIV) in vivo is not prevented by a strong cellular and humoral
response against HIV type 1 (HIV-1). Antibody production and
cell-mediated immunity are often reciprocal immune responses associated
with distinct patterns of cytokine production by two subsets of
CD4+ T-helper (TH) cells. Cells of the
TH1 subset secrete interleukin-2 (IL-2) and gamma
interferon (IFN-
) but not IL-4 or IL-5 and are associated with
cell-mediated responses such as delayed-type hypersensitivity; TH2 cells secrete IL-4 and IL-5 but not IFN-
and are
associated with antibody and allergic responses (36, 50, 51, 55, 57). These cytokines are also secreted by other cell types, contributing to overlapping patterns of cytokine expression which may
complicate our understanding of mechanistic issues involved in the
immune response.
During microbial infections, particularly chronic persistent
infections, there can be a preferential development of one of the
TH lineages. Simply, infections by viruses and
intracellular pathogens are often better controlled by cellular
(TH1 and cytotoxic T-cell) responses, whereas infections by
parasites and bacteria may be controlled more effectively by
antibody-TH2 responses (14, 15, 51, 57).
However, while the development of the correct immune response is
critical in host resistance to microbes, some infectious agents can
stimulate inappropriate cytokine responses, contributing to increased
disease pathology (1). As CD4+ T cells are the
preferential targets of HIV, much interest and controversy have
developed regarding a role for the TH1 and TH2 cells and cytokines during HIV infection and their relationship to HIV
pathogenesis (3, 9-12, 31, 43-46, 49, 56).
Studies by Maggi et al. (43) suggest that HIV replicates
preferentially in TH2 and TH0 rather than
TH1 clones in vitro. This concept has been incorporated in
recent models of HIV pathogenesis (11, 49, 56). Since the
complex nature of virus-cell interactions as well as the extracellular
environment can often affect the kinetics and magnitude of viral
replication, HIV replication and cell survival were examined in a panel
of human antigen-specific CD4+ TH1 and
TH2 clones. After activation by specific antigens and infection with HIV-1, TH1 and TH2 clones,
developed from healthy donors, showed similar levels of strong-stop and
full-length viral DNA. Regardless of the tropism of virus used, HIV
replicated to similar levels in several TH1 and
TH2 clones. When values were normalized for viable cell
number, there was up to twofold more HIV-1 RNA in TH1 than
TH2 cells, indicating that there is little difference in
the ability of TH1 and TH2 subsets to support
HIV replication in vitro.
 |
MATERIALS AND METHODS |
Derivation and maintenance of antigen-specific human
CD4+ T-cell clones.
Purified protein derivative
(PPD)-specific, tetanus toxoid (TTx)-specific, keyhole limpet
hemocyanin (KLH)- and Dermatophagoides pteronyssinus antigen
(DP)-specific, and staphylococcal enterotoxin B (SEB)-reactive T-cell
clones were generated as previously described (25, 28). PPD
and TTx were purchased from Connaught, Inc. (Swiftwater, Pa.), SEB was
purchased from the Sigma Chemical Company (St. Louis, Mo.), and DP and
KLH were purchased from Miles, Inc. (Spokane, Wash.). Briefly,
peripheral blood mononuclear cells (PBMCs) at a concentration of 5 × 105 cells/ml in clone medium (EHAA [Click's] medium
supplemented with L-glutamine, 2-mercaptoethanol, 2% human
AB serum, 10% fetal calf serum, penicillin-streptomycin, nonessential
amino acids, and sodium pyruvate; Life Technologies, Gaithersburg, Md.)
were stimulated with either PPD (1 µg/ml), TTx (10 µg/ml), DP (10 IU/ml), or SEB (0.1 µg/ml) in 24-well flat-bottom plates for 7 days.
Many but not all of the TH1 and TH2 clones used
in these studies were derived in cultures supplemented with the
TH cell selective cytokines, IL-4 and IL-12. For the
generation of TH1 clones, these cultures were supplemented
with recombinant human IFN-
(rhIFN-
; 10 U/ml; Peprotech, Rocky
Hill, N.J.), rhIL-12 (50 pg/ml; Roche, Nutley, N.J.), and anti-IL-4
monoclonal antibody (MAb; 10 µg/ml; R&D Systems, Minneapolis, Minn.)
over the culture period. For TH2 clones, bulk cultures were
supplemented with rhIL-4 (200 U/ml; Peprotech) and anti-IFN-
MAb (10 µg/ml; R&D Systems). Forty-eight hours after the initiation of these
cultures, rhIL-2 (10 U/ml) was added to each of the wells. After 7 days
of incubation, the cultures were harvested, extensively washed,
replated in fresh clone medium supplemented with additional IL-2 (10 U/ml; Cellular Products, Buffalo, N.Y.), and incubated for an
additional 7 to 10 days. Viable T cells were then plated in
limiting-dilution cultures (0.5 cells/well) in 16 flat-bottom 96-well
plates containing 2 × 105 irradiated (1,200 rads)
syngeneic PBMC feeder cells, specific antigen, and IL-2 (10 U/ml) in a
final volume of 200 µl. The cultures were examined daily and
supplemented with the TH1- and TH2-selecting cytokines (as described above) at 10-day intervals with feeder cells
and IL-2. Individual clones were isolated and then characterized for
lymphokine production by enzyme-linked immunosorbent assay (ELISA) and
PCR analysis and for the ability to respond to specific antigen in
combination with syngeneic irradiated (1,200 rads) feeder cells.
To maintain TH clones, cells were restimulated every 14 to
21 days with specific antigen in the presence of autologous PMBCs treated with mitomycin C at 25 µg/ml to prevent outgrowth of feeder cells and IL-2 (20 U/ml). After 96 h of antigenic stimulation, cells were subjected to two successive Ficoll-Hypaque centrifugations to remove dead cells. All clones were tested for their cytokine profiles by ELISA after stimulation with a combination phorbol myristate acetate (PMA) and monoclonal anti-CD3 as well as with antigen
and antigen-presenting cells to determine the phenotype of each clone.
Chemokine binding assays.
Binding conditions for CC
chemokines MIP-1
, MIP-1
, RANTES, MCP-1 and MCP-3 and the CXC
chemokine IL-8 were as previously described (58, 61).
Briefly, 2 × 106 cells were incubated in duplicate or
triplicate (depending on the availability of the clones) with
increasing concentrations of 125I-labeled chemokines in a
modified binding medium (RPMI 1640 with 1 mg of bovine serum albumin
per ml, 25 mM HEPES, and 0.05% sodium azide [pH 7.4]) in a total
volume of 200 µl. The residual nonspecific binding was determined by
parallel incubation of 125I-labeled chemokine in the
presence of a 100-fold excess of unlabeled chemokine. After incubation
at 4°C or room temperature for 90 min, the cells were pelleted
through a 10% sucrose-phosphate-buffered saline (PBS) cushion. The
tips of the tubes containing cells were cut, and radioactivity was
quantitated in a gamma counter. The residual nonspecific bound
radioactivity associated with cells in the presence of unlabeled
chemokine was subtracted from the total bound radioactivity to yield
specific binding. The data were analyzed with the Biosoft RADLIG
program.
Chemokine receptor flow cytometric analysis.
Phycoerythrin
and fluorescein isothiocyanate-labeled rabbit antibodies specific for
human CXCR4, CCR5, CXCR1, CXCR2, and CD4 were obtained from R&D
Systems. Polyclonal rabbit anti-CCR1 antibody was generously provided
by Richard Horuk (Berlex Biosciences, Richmond, Calif.). Flow
cytometric staining and analysis were performed as previously described
(52, 61). The data are expressed as percent positive (± standard deviation) and/or as mean channel fluorescence.
HIV infection of T-cell clones.
Antigen-stimulated clones
(2 × 106 cells/0.5 ml), 4 to 7 days postactivation
(>95% viable by trypan blue exclusion), were inoculated with
cell-free viral isolates with a total of 100 pg of HIV p24 and allowed
to adsorb for 90 min at 37°C in a shaking water bath before complete
aspiration of medium, washing with PBS, and addition of fresh growth
medium containing IL-2 (20 U/ml). Cells were aliquoted at
106 cells/ml in 24-well plates. Three laboratory
T-cell-tropic (syncytium-inducing [SI]) strains of HIV used were BP1
(48), IIIB, and MN (purified 1,000-fold; kindly provided by
the AIDS vaccine program, Frederick, Md.). These viral stocks were
grown in H9 cells. The primary monocytotropic (non-SI [NSI]) viruses,
SF162, US657, US714, and US727, were obtained from the AIDS Reference
and Reagent Program. These stocks were grown in primary PBMCs.
Quantitation of cytokine and p24 production by T-cell
clones.
Quantitative determinations for lymphokines (human IL-2,
IL-4, IL-5, IL-10, and IFN-
) from the 48-h supernatants of
antigen-stimulated T-cell clones were done by ELISA (Quantikine; R&D
Systems) by following the manufacturers' instructions. The results are
expressed in either nanograms/milliliter or units/milliliter based on a standard curve determined by using recombinant cytokine within the
ELISAs. Cytokine analyses after HIV infection were performed with
cell-free supernatants and were quantitated by ELISA for IL-4, IL-5
(R&D Systems), and IFN-
(Medigenix) with sensitivities of 3 pg/ml, 1 pg/ml, and 1 IU/ml, respectively. Viral p24 antigen was determined by
ELISA (Cellular Products) with a sensitivity of 10 pg/ml. To determine
the portion of the cells productively infected, flow cytometry for
intracellular expression of HIV-1 p24 was performed with
rhodamine-conjugated anti-p24 antibody.
Detection of HIV-1 DNA in T-cell clones.
For the detection
of viral DNA, cell lysates were made by incubating 106
cells in 100 µl of lysis buffer (10 mM Tris HCl [pH 8], 1 mM EDTA,
0.001 mM Triton X-100-sodium dodecyl sulfate, 1 mg of proteinase K per
ml) at 60°C for 1 h followed by 99°C for 10 min to inactivate the proteinase K. Quantitative PCR amplification was performed with one
oligonucleotide of each pair end labeled with 33P, and 25 ng was used in each reaction (5 × 105 to 5 × 106 cpm). The samples were denatured for 5 min at 94°C
followed by 25 cycles of denaturation for 1 min at 91°C and
annealing-extension for 2 min at 65°C (63). Primers for
minus strong-stop HIV-1 R and U5 (140 bp), sense
(5'-GGCTAACTAGGGAACCCACGT-3') and antisense (5'-CTGCTAGAGATTTTCCACACTGAC-3'), and for HIV-1 long
terminal repeat (LTR) and gag (200 bp), sense
(5'-CTGCTAACTAGGGAACCCACGT-3') and antisense
(5'-CCTGCGTCGAGAGAGCTCCTCTGG-3'), were previously described
by Zack et al. (63). The primers LA1 and LA2 (63) for human
-globin were included as a control for amplification. Products were separated by electrophoresis on an 8% nondenaturing acrylamide gel. Dried gels were analyzed on a PhosphorImager (Molecular Dynamics, San Diego, Calif.), quantitated with ImageQuant and Microsoft
Excel software, and exposed to Kodak XAR-5 film at
70°C overnight.
HIV-1 copy numbers per 50,000 cells/lane were estimated by comparing
graded doses of ACH-2 DNA lysate; this cell line contains 1 proviral
copy/cell (26).
RT-PCR analysis of cytokine and HIV-1 RNA.
RNA was prepared
from 106 cells by using RNA Stat 60 (Tel Test Inc.,
Friendswood, Tex.). Reverse transcription of 5 µg of RNA was
performed with Superscript II reverse transcriptase (RT) (Life Technologies). One to two microliters of the reaction mixture was used
in each amplification. Primer pairs for cytokine detection were
purchased as RT-PCR Amplimer sets (Clontech, Palo Alto, Calif.). Primers SK38 and SK39 for HIV gag (positions 1543 to 1570 and 1630 to 1657) (6) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (371 to 388, 546 to 565) (29) were
previously described. Amplification was carried out in the presence of
[32P]dCTP as previously described (17).
Products were separated by electrophoresis on an 8% nondenaturing
acrylamide gel. Dried gels were analyzed on a PhosphorImager (Molecular
Dynamics), quantitated with ImageQuant and Microsoft Excel software,
and exposed to Kodak XAR-5 film at
70°C for 1 to 4 h. GAPDH
was always used as a control for amplification.
In vitro synthesis of HIV-1 RNA.
HIV-1 RNA synthesized from
a DNA template produced by the amplification of HIV-1 proviral DNA by
using modified HIV-1 gag region-specific primers SK38 and
SK39 (64) was kindly provided by B. Poiesz (State University
of New York, Syracuse). Briefly, primer SK38 was altered by the
addition of the T3 RNA polymerase promoter sequence
(5'-CCCTATAGTGAGTCGTATTA-3'), in inverse complementary orientation, to the 5' end of the original primer sequence. An additional five bases (GGTCG) upstream of the promoter site were included to ensure more efficient binding of the RNA polymerase. The
modified primer, RPSK38, was used with primer SK39 to amplify 1 µg of
HUT 78/HIVAAV DNA by PCR. The resulting product was
separated by electrophoresis on and excised from a native 10%
polyacrylamide gel and eluted into 50 µl of diethyl
pyrocarbonate-treated H2O. Ten microliters of this HIV-1
gag DNA was then mixed with 40 µl of RNA synthesis
cocktail containing 10 µl of 5× reaction buffer (Life Technologies),
400 U of RNasin (Promega, Madison, Wis.), 100 U of T7 RNA polymerase
(Stratagene, La Jolla, Calif.), 2.5 µl of 100 mM dithiothreitol, and
2 µl each of 10 mM deoxynucleoside triphosphates in diethyl
pyrocarbonate-treated H2O. After incubation at 37°C for
1 h, 4 U of RQ1 DNase was added to digest the template DNA. The
resulting HIV-1 single-stranded gag RNA was separated on and
eluted from a native 10% polyacrylamide gel and serially used as an
RNA standard in RT-PCR assays. For quantitation, RNA was diluted until
its signal was in the linear range of the standard curve, using 1,000 to 2,000 RNA molecules, and dried gels were analyzed on a
PhosphorImager (Molecular Dynamics), quantitated with ImageQuant and
Microsoft Excel software, and exposed to Kodak XAR-5 film at
70°C
for 1 to 4 h.
Statistics.
Means and standard error of the mean (SEM) were
calculated for the results of HIV p24 antigen determination.
 |
RESULTS |
Generation and characterization of antigen-specific TH
clones.
TH cell clones were derived from three
different non-HLA-matched healthy PBMC donors as described in Materials
and Methods. In contrast to mice, human TH1 and
TH2 phenotypes are less restricted in cytokine expression
in that both subsets produce IL-2 and IL-10 (14, 55, 56).
Therefore, we used RT-PCR to in addition to ELISAs to pedigree each of
these antigen-specific T-cell clones. Using these criteria, we found
numerous TH0 clones regardless of whether TH1-
or TH2-promoting media were used (Fig.
1). The TH1 clones used in
these studies were specific for either TTx, DP, SEB, or PPD, while
TH2 clones were specific for DP or TTx. All of the T-cell
clones used expressed similar cell surface phenotypes (CD4+, CD8
, CD3+,
CD19
, CD56
, CD16
, and
CD14
) as determined by flow cytometric analysis and were
found to proliferate in response to specific but not irrelevant
antigens (data not shown). All TH1 clones used were
negative for IL-4 and IL-5 and positive for IFN-
by ELISA (Tables
1 and 2)
and IL-4 negative and IFN-
positive by RT-PCR (representative clones
are shown in Fig. 1A). Similarly, all of the TH2 clones
used were negative for IFN-
and positive for IL-4 and IL-5 by ELISA
(Tables 1 and 2) and IFN-
negative and IL-4 positive by RT-PCR
(representative clones are shown in Fig. 1B). All TH1 and
four of seven TH2 clones also produced IL-2. All clones
producing a combination of TH1 and TH2
lymphokine mRNAs were designated TH0 (Fig. 1; Table 2) and
not used for HIV infection.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Characterization of human TH clones by
RT-PCR. Single-cell cloning of human peripheral blood was performed as
described in Materials and Methods. Presence of mRNA for IFN- and
IL-4 in these clones was measured 7 days after antigen activation,
using RT-PCR as described in Materials and Methods. (A) Clones isolated
under TH1 conditions. Lane 1, IFN- ; lane 2, IL-4; lane
3, GAPDH. Arrows indicate positions of cytokine standards. (B) Clones
isolated under TH2 conditions. Lane 1, standard (STD) for
IL-4 (427 bp); lane 2, standard for IFN- (459 bp) (Clontech). GAPDH
(not shown) was used as a loading control.
|
|
Similar levels of HIV receptors on the cell surface of
antigen-activated TH cell clones.
The recent
demonstration that CC chemokines can inhibit HIV-1 infection
(13) followed by the finding that selected CC and CXC
chemokine receptors (8, 16, 19, 20, 23, 38) act as cofactors
with CD4+ to mediate viral entry into cells represents a
significant advance in our understanding of HIV infectivity. Different
strains of HIV-1 use different chemokine receptors for cell entry:
macrophage-tropic HIV-1 strains mainly use CCR5 (8, 16, 20)
and to a lesser extent CCR3 and CCR2b (19), while
T-cell-tropic strains use CXCR4 (23, 38). Therefore, we
analyzed the cell surface expression of HIV-1 receptors on
TH1, TH2, and TH0 clones 4 to 5 days after antigen activation. Regardless of the TH subset
of the clones, they expressed detectable levels of CXCR4 and CCR5 by
flow cytometry analysis whereas expression of CXCR1 and CCR1 was
variable (Table 2). The densities (the amount of antigen as measured by
the mean channel fluorescence) of these molecules as well as CD4 and
CD44 expression on the cell surface were also similar on
TH1 and TH2 clones (Fig.
2; Table
3). The density of CXCR4 was consistently higher than the density of CCR5 on these activated TH cells
regardless of subset. Scatchard analysis showed that the number and
affinity (Kd) of binding sites for CC and CXC
chemokines were similar on TH1 and TH2 clones
(Table 4).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Flow cytometric analysis of a human TH1
clone and a human TH2 clone for cell surface expression of
chemokine receptors. A total of 106 cells of each of the
T-cell clones H1.5 and H2.25 were suspended in PBS containing 1%
heat-inactivated human AB serum and 0.5% sodium azide and stained with
phycoerythrin (PE)-labeled anti-CXCR2, -CXCR4, -CD4, or -CD44 or an
isotype control labeled immunoglobulin G antibody. After staining, the
cells were extensively washed and then fixed with 1% paraformaldehyde.
The clones were analyzed on a FACStar Plus flow cytometer.
|
|
Similar levels of HIV-1 entry in antigen-activated TH
cell clones.
Three different TH1 and TH2
clones were exposed to a filtered RNase-free DNase I-treated
preparation of HIV-1IIIB for 90 min at 37°C, washed, and
recultured. At various time points postinfection (p.i.), aliquots of
cells (105) were removed and lysates were prepared for PCR
analysis of HIV-1 DNA. In the PCR method previously described by Zack
et al. (63), primer pairs were designed to detect certain
steps of the reverse transcription process by using the accepted model
for reverse transcription of retroviral RNA. Amplification using the
R-U5 primer pair detects a DNA region representing initial reverse transcription, and nearly complete reverse transcription is detected with the LTR-gag primer pair. The sensitivity of the
amplification was similar in TH1 and TH2
clones, equaling 5 to 10 copies of HIV DNA. As there is evidence that
HIV-1 virions can contain short transcripts and DNA (42,
60), we used a heat-inactivated virus preparation as a control in
all infections. No signal was detected either in this control or in
aliquots taken 90 min after HIV exposure (data not shown). By 24 h
p.i., 2,000 to 5,000 copies of R-U5 and 100 to 500 copies of
LTR-gag DNA (Fig. 3) were
seen. No significant differences in copy number of R-U5 or
LTR-gag DNA were observed between TH1 and
TH2 clones at 24 h (Fig. 3), indicating similar levels
of viral entry and reverse transcription in these antigen-specific TH1 and TH2 clones.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
HIV-1 DNA detection in TH1 and
TH2 clones. Lysates were prepared 24 h p.i. A primer
pair was used to detect the earliest region of DNA formed by reverse
transcription (141 bp of the minus strong-stop strand). Another primer
pair was used to detect full-length HIV-1 DNA (200 bp of
LTR-gag). The sense primers of each pair were radiolabeled.
Three different TH1 (H1.12, H1.15, and H1.18) and
TH2 (H2.25, H2.29, and H2.33) clones shown for each
infection are representative of three separate experiments. Tenfold
serial dilutions of the ACH-2 cell line, containing one integrated copy
of HIV-1 DNA per cell, were made in a background of uninfected T cells
and shown for estimation of copy number.
|
|
Similar levels of replication by SI HIV strains in
antigen-activated TH cell clones.
Next, the ability of
these clones to support HIV replication in vitro was evaluated. Clones
(>95% viable following Ficoll-Hypaque separation) were infected
between 4 and 7 days after antigen stimulation, using the specific
antigen and mitomycin C-treated autologous PBMC feeder cells. Using two
T-cell-tropic laboratory viral strains, BP1 (48) and IIIB,
all seven TH1 and seven TH2 clones released substantial amounts of extracellular p24 at days 7 and 14 p.i. (Table
5). At day 7, for example, infected
TH1 and TH2 clones released similar levels of
virus, with ranges of p24 being 22,500 to 47,500 pg/ml for
TH1 clones and 23,000 to 57,000 pg/ml for TH2
clones (Table 5). Furthermore, results obtained with clones infected
with the BP1 strain (Table 5, clones 1 to 7) were indistinguishable from those obtained with clones infected with the IIIB strain (Table 5,
clones 8 to 14). Infected TH1 cells (day 10 p.i.)
maintained a TH1 phenotype in that the infected cultures
were positive for IFN-
mRNA but not for IL-4 mRNA; infected
TH2 cells remained IFN-
negative and IL-4 mRNA positive
(data not shown). By fluorescence-activated cell sorting analysis, for
HIV-1 p24, the number of positive cells at day 7 ranged from 47 to
72%, with no differences seen between infected TH1 and
TH2 clones (data not shown).
In addition, the number of HIV gag RNA molecules per
microgram of total RNA was determined by using a dilution of a standard number of RNA molecules determined as previously described
(64) (Fig. 4). At day 2 p.i. HIV-1-infected TH1 cells had approximately 500 gag RNA molecules/µg of RNA (Fig. 4, lane 1), while
mitogen-stimulated mitomycin-treated feeder cells expressed no viral
RNA (Fig. 4, lane 3). At day 7, a substantial number of gag
RNA molecules were present in both TH1 and TH2
clones (Fig. 4). To obtain more precise numbers, the viral RNA was
diluted to 1,000 to 2,000 molecules/reaction so that the signal
obtained under the amplification conditions used was in the linear
range of the standard curve. Using this approach, we determined that
similar numbers of gag RNA molecules were present in
different TH1 and TH2 clones throughout the
duration of the infection (Table 6).
Thus, although different clones varied two- to threefold in number of
mRNA molecules present (8,000 to 25,000 molecules/µg of RNA), neither
the kinetics nor the magnitude of HIV expression in TH2
clones was significantly higher than in TH1 clones
regardless of the viral isolate used to infect the clones (Tables 5 and
6). We also investigated whether the antigen specificity of the clones
made a difference by measuring RNA at day 7 p.i.; in the case of a
SEB TH1 and TH2 clone, there was little
difference in number of viral RNA molecules (9,500 versus 10,800).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of HIV gag mRNA in HIV-infected
TH1 and TH2 clones. HIV infection of
antigen-activated T-cell clones, RT-PCR analysis, and use of HIV
gag RNA standards were performed as described in Materials
and Methods. Cells were infected with HIVMN. Lanes 1 and 2, TH1 H1.15 with and without HIV, day 2; lanes 3 and 4, mitogen-stimulated antigen-presenting cells (APC) with and without HIV,
day 2; lanes 5 and 6, TH1 H1.15 with and without HIV, day
7; lane 7, TH1 H1.12 with HIV, day 7; lanes 8 and 9, TH2 H2.29 with and without HIV, day 7; lane 10, TH2 H2.29; lane 11, TH2 H2.29 with HIV, day 14;
lanes 12 to 16, RNA standard curve.
|
|
Since accelerated cell death has been seen in HIV-infected T cells
following in vitro stimulation (2, 24, 32, 39, 47, 59), it
is possible that if the data were based on input cell number, the
results could vary between clones. When the number of HIV
gag molecules per 105 viable cells (measured by
trypan blue exclusion and Ficoll-Hypaque separation) was determined,
the infected TH1 cells were found to contain roughly
twofold more RNA molecules than infected TH2 clones (Table
7). In addition, when a TH1
clone activated with either specific antigen or PMA-anti-CD3 was
infected with HIV, similar levels of replication were observed in this
TH1 clone (Table 7). Thus, even when potential differences
in cell viability or polyclonal activation are taken into account, we
did not observe any preferential replication of HIV-1 in TH
subsets.
Infection of TH1 and TH2 clones by primary
NSI HIV-1 strains.
The different tropism (primary macrophages and
T cells but not T-cell lines) of primary NSI strains from SI strains
suggested a possible difference in infecting different T-cell clones.
To investigate this, we infected three TH1 and three
TH2 clones highly susceptible to infection by laboratory SI
strains with four primary well-characterized NSI isolates. As discussed
earlier, amplification using the R-U5 primer pair detects a DNA region
representing initial reverse transcription and nearly complete reverse
transcription is detected with the LTR-gag primer pair (Fig.
5). At 12 h p.i., the SF162 strain did not show detectable viral
entry in two of three clones of each type, while the other three NSI
strains showed equivalent strong-stop DNA in each clone, with little
variation between TH1 and TH2 clones. At 7 days
p.i., the amount of full-length viral DNA present in the cells (Fig.
5) and the amount of HIV-1 p24 in the
supernatant (Table 8) show clear clonal
variations in ability to support viral infection. The TH1
clones H1.20 and H1.25 and the TH2 clones H2.10 and H2.5
supported vigorous replication with three of four NSI viral isolates,
while the TH1 clone H1.15 and the TH2 clone
H2.33 poorly supported NSI viral replication (Table 8). There was also
variation between viral isolates, with SF162 being poorly replicative
in the four clones in which the three other NSI viruses replicated
well.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
HIV-1 DNA detection in TH1 and
TH2 clones. Lysates were prepared at 10 and 24 h p.i.
A primer pair was used to detect the earliest region of DNA formed by
reverse transcription (141 bp of the minus strong-stop strand). Another
primer pair was used to detect full-length HIV-1 DNA (200 bp of
LTR-gag) and human -globin. The sense primers of each
pair were radiolabeled. Two different TH1 (H1.20 and H1.25)
and TH2 (H2.10 and H2.25) clones are shown. Lanes: A,
control; B, SF162 infection; C, US657; D, US714; E, US727. Tenfold
serial dilutions of the ACH-2 cell line, containing one integrated copy
of HIV-1 DNA per cell, were made in a background of uninfected T cells
and shown for estimation of copy number.
|
|
 |
DISCUSSION |
CD4+ T cells, the preferential targets of HIV-1, can
be divided into functional TH1 and TH2 subsets
which are responsible for initiating the immune response against
different classes of foreign invaders (14, 15, 50, 51, 57).
Since alterations in the TH1 and TH2 responses
can increase microbial pathogenesis, much effort has gone into
determining the role of TH1 and TH2 cells and
cytokines during HIV infection and their relationship to HIV
pathogenesis. Whether there is an alteration in TH1 and TH2 responses during AIDS progression remains controversial
(3, 9-12, 31, 43-46, 49, 56).
One study by Maggi et al. (43) has suggested that HIV
replicates preferentially in TH2 and TH0 clones
rather than TH1 clones in vitro. This concept could have
major implications in AIDS pathogenesis and has been incorporated in
recent models of HIV pathogenesis (11, 49, 56). As the
kinetics and magnitude of a viral infection can often be affected by
the nature of virus-cell interactions as well as extracellular
environment, we examined HIV infectivity in a panel of defined human
TH cell clones derived from different donors. Since
cytokine secretion by TH cells is a continuum and TH2 and TH1 subsets represent the polar ends of
the TH cell spectrum (36, 51, 55, 57), we used
well-defined TH1 clones (IFN-
+
IL-4
IL-5
) and TH2 clones
(IFN-
IL-4+ IL-5+) in this
study. Neither mitogen (PMA-anti-CD3) treatment nor HIV infection
altered the cytokine patterns produced by TH1 and TH2 clones.
We observed no significant differences between TH1 and
TH2 clones with respect to (i) the cell surface expression
of CD4 and the chemokine receptor cofactors (both CXC and CC classes),
(ii) viral entry and reverse transcription (measured by strong-stop and
full-length HIV-1 DNA), and (iii) HIV replication (measured by release
of HIV p24 and total number of copies of gag RNA per total
cell RNA). The results were similar whether the virus used was a
laboratory SI strain or a primary NSI strain. In the case where a virus
replicated poorly, it did so in both types of TH cells.
Even though the amount of gag mRNA molecules could be an overestimate due to the presence of some viral genomic RNA, there is
unlikely to be significantly more genomic RNA in one subset than
another. Thus, we did not observe any preferential HIV infection of
activated TH2 over TH1 clones in vitro. In the
production of viral p24, additional parameters, such as the use of
different T-cell donors for cell cloning and the use of different
antigenic specificities, had no effect on the results. The presence of
substantial amounts of CD4, CD44 (21), and CCR5 (8, 16,
19, 20) on the cell surface of TH1 and
TH2 clones used supports the similar production seen with
monocytotropic HIV-1 strains and suggests these T-cell clones are more
like primary T cells (30, 63) than T-cell lines.
In using NSI strains of HIV to infect these clones, we found, as
previously reported, clonal variation in that some clones would not
support replication of these viruses (27, 44) very well as
well as variation in the ability of these viruses to replicate in
permissive clones. However, these differences were not restricted to
either TH1 or TH2 clones. Thus, there are not
likely to be any intrinsic differences in the ability of different
types of T-cell clones to support HIV-1 replication. However, there
could be many environmental reasons for differences in HIV replication, such the amount of chemokines released (13, 22), the absence of coreceptors on certain types of clones (41), and the
ability of immune stimulation to preferentially downregulate the CCR5 coreceptor (4, 7).
In the study by Maggi et al. (43) and other studies
(34, 54, 57), TH clones were activated by
mitogens (such as PMA-anti-CD3), as it was believed that cells express
a more heterogeneous cytokine pattern after mitogen activation than
after antigen activation. Therefore, mitogen stimulation would result
in uncovering more TH0 clones. However, we did not find any
difference between antigen and mitogen activation on viral replication
or cytokine production in TH1 clones. Indeed, our results
are similar to those of other studies which, when measuring cytokine
production at the single-cell level, found no qualitative differences
in cytokine profiles between antigen and mitogen stimulation (36,
54). In addition, HIV-infected TH1 and
TH2 clones still maintained the same phenotype as measured by cytokine profile 10 days after infection. Recent evidence that memory and naive CD4+ T cells (precursors of both
TH1 and TH2 cells) from HIV-infected individuals have similar rates of decline during AIDS progression (45, 46), and the ability to obtain high percentages of both TH1 and TH2 clones from PBMCs of late-stage
AIDS patients (43, 47, 56) despite the daily loss and
replacement of CD4+ T cells during HIV infection (33,
62) makes it unlikely that there is preferential infection of
CD4+ TH cell subsets in vivo during AIDS
progression.
Maggi et al. (43), who found no evidence for in vitro
infection of TH1 clones by HIV, examined only one time
period (20 days p.i.) in their study. While the differences between the
two studies could be due to several factors (differences in
experimental design, differences in the panel of clones used, methods
of T-cell activation, etc.), the time point used to measure HIV-1
production is close to the limit of T-cell clone survival without
further stimulation with antigen and feeder cells. Since both infected and uninfected T cells from HIV-infected individuals undergo activation induced apoptosis in vitro (2, 24, 32, 39, 47, 59) probably
through Fas-mediated killing (5, 18, 34, 35, 37, 53), one
possible reason for the discrepancy between the two studies is
differential cell death of the infected TH1 and TH2 clones. Differences in virus production in vitro at
later times of infection could be due to more rapid killing of one
subset. However, when values were normalized for viable cell number,
more gag RNA molecules were found in TH1 cells.
These studies indicate that any role of TH1 and
TH2 subsets in AIDS pathogenesis transcends clonal
differences in their ability to support HIV replication.
 |
ACKNOWLEDGMENTS |
We thank Bernard Poiesz for providing the HIV gag RNA
standard and Cari Petrow, Jason Troxell, and Anne Meyers for excellent technical assistance. The HIV primary isolates were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Leukocyte Biology, NCI-Frederick Cancer Research and Development
Center, Bldg. 567, Rm. 254, Frederick, MD 21702-1201. Phone: (301)
846-1504. Fax: (301) 846-7034. E-mail: RuscettF{at}ncifcrf.gov.
 |
REFERENCES |
| 1.
|
Aggarwal, B., and R. Puri (ed.).
1995.
In
Human cytokines: their role in disease and therapy.
Blackwell Science, Cambridge, Mass.
|
| 2.
|
Ameisen, J.
1992.
Programmed cell death and AIDS: from hypothesis to experiment.
Immunol. Today
13:388-391[Medline].
|
| 3.
|
Barcellini, W.,
G. Rizzardi,
M. Borghi,
C. Fain,
A. Lazzarin, and P. Meroni.
1994.
TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients.
AIDS
8:757-762[Medline].
|
| 4.
|
Bleul, C.,
L. Wu,
J. Hoxie,
T. Springer, and C. MacKay.
1997.
The HIV coreceptors CXCR4 and CCR5 are differently expressed and regulated on human T lymphocytes.
Proc. Natl. Acad. Sci. USA
94:1925-1930[Abstract/Free Full Text].
|
| 5.
|
Brunner, T.,
R. Mogli,
D. LaFace,
N. Yoo,
A. Mahboubi,
F. Echeverri,
S. Martin,
W. Force,
D. Lynch,
C. Ware, and D. Green.
1995.
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.
Nature
373:441-444[Medline].
|
| 6.
|
Byrne, B.,
J. Li,
J. Sninsky, and B. Poiesz.
1988.
Detection of HIV RNA sequences by in vitro DNA amplications.
Nucleic Acids Res.
16:4165[Free Full Text].
|
| 7.
|
Carroll, R.,
J. Riley,
B. Levine,
Y. Feng,
S. Kaushal,
D. Ritchey,
W. Bernstein,
O. Weislow,
C. Brown,
E. Berger,
C. June, and D. St. Louis.
1997.
Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells.
Science
276:273-276[Abstract/Free Full Text].
|
| 8.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. D. Ponath,
L. Wu,
C. R. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[Medline].
|
| 9.
|
Clerici, M., and G. Shearer.
1993.
A TH1-TH2 switch is a critical step in the etiology of HIV infection.
Immunol. Today
14:107-110[Medline].
|
| 10.
|
Clerici, M.,
F. Hakim,
D. Venzon,
S. Blatt,
C. Hendrix,
T. Wynn, and G. Shearer.
1993.
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.
J. Clin. Invest.
91:759-765.
|
| 11.
|
Clerici, M., and G. Shearer.
1994.
The Th1-Th2 hypothesis of HIV infection: new insights.
Immunol. Today
15:575-581[Medline].
|
| 12.
|
Clerici, M.,
T. Wynn,
J. Berzofsky,
S. Blatt,
C. Hendrix,
A. Sher,
R. Coffman, and G. Shearer.
1994.
Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with human immunodeficiency virus.
J. Clin. Invest.
93:768-775.
|
| 13.
|
Cocchi, F.,
A. L. DeVico,
A. Garzino-Demo,
S. K. Arya,
R. C. Gallo, and P. Lusso.
1995.
Identification of RANTES, MIP-1 , and MIP-1 as the major HIV-suppressive factors produced by CD8+ T cells.
Science
270:1811-1815[Abstract/Free Full Text].
|
| 14.
|
Del Prete, G.,
M. De Carli,
C. Mastromauro,
D. Macchia,
R. Biagiotti,
M. Ricci, and S. Romagnani.
1991.
Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production.
J. Clin. Invest.
88:346-352.
|
| 15.
|
Del Prete, G., and S. Romagnani.
1994.
The role of TH1 and TH2 subsets in human infectious diseases.
Trends Microbiol.
2:4-6[Medline].
|
| 16.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Marzio,
S. Marmon,
R. Sutton,
C. Hill,
C. Davis,
S. Peiper,
T. Schall,
D. Littman, and N. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 17.
|
Derse, D.,
J. Mikovits,
M. Polianova,
B. K. Felber, and F. Ruscetti.
1995.
Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells.
J. Virol.
69:1907-1912[Abstract].
|
| 18.
|
Dhein, J.,
H. Walczak,
C. Baumler,
K. Debatin, and P. Krammer.
1995.
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).
Nature
373:438-441[Medline].
|
| 19.
|
Doranz, B.,
J. Rucker,
Y. Yi,
R. Smyth,
M. Samson,
S. Peiper,
M. Parmentier,
R. Collman, and R. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors.
Cell
85:1149-1158[Medline].
|
| 20.
|
Dragic, T.,
V. Litwin,
G. Allaway,
S. Martin,
Y. Huang,
K. Nagashima,
C. Cayanan,
P. Maddon,
R. Koup,
J. Moore, and W. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature
381:667-673[Medline].
|
| 21.
|
Dukes, C.,
Y. Yu,
E. Rivadeneira,
D. Sauls,
D. H.-X. Liao,
B. Haynes, and J. Weinberg.
1995.
Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism.
J. Virol.
69:4000-4005[Abstract].
|
| 22.
|
Fauci, A.
1996.
Host factors and the pathogenesis of HIV-induced disease.
Nature
384:529-534[Medline].
|
| 23.
|
Feng, T.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 24.
|
Finkel, T.,
G. Tudor-Williams,
N. Banda,
M. Cotton,
T. Curiel,
C. Monks,
T. Baba,
R. Ruprecht, and A. Kupfer.
1995.
Apoptosis occurs predominately in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes.
Nat. Med.
1:129-134[Medline].
|
| 25.
|
Fitch, F., and T. Gajewski.
1991.
Production of T cell clones, p. 3.13.1-3.13.9.
In
J. Coligan, A. Kruisbeek, D. Margulies, E. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
|
| 26.
|
Folks, T.,
D. Powell,
M. Lightfoote,
S. Benn,
M. Martin, and A. Fauci.
1986.
Induction of HTLV-III/LAV from a non-virus producing T cell line: implications for latency.
Science
231:600-602[Abstract/Free Full Text].
|
| 27.
|
Fouchier, R.,
L. Meyaard,
M. Brouwer,
E. Hovenkamp, and H. Schuitemaker.
1996.
Broader tropism and higher cytopasticity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo.
Virology
291:87-95.
|
| 28.
|
Gajewski, T. F.,
D. W. Lancki,
R. Stack, and F. W. Fitch.
1994.
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.
J. Exp. Med.
179:481-491[Abstract/Free Full Text].
|
| 29.
|
Gendelman, H.,
R. Friedman,
S. Joe,
L. Baca,
J. Turpin,
G. Dveksler,
M. Meltzer, and C. Dieffenbaker.
1990.
A selective defect of interferon-alpha production in human immunodeficiency virus-infected monocytes.
J. Exp. Med.
172:1433-1440[Abstract/Free Full Text].
|
| 30.
|
Granelli-Piperno, A.,
B. Mose,
M. Pope,
D. Chen,
Y. Wei,
F. Isdell,
U. O'Doherty,
W. Paxton,
R. Koup,
S. Mojsov,
N. Bhardwaj,
I. Clark-Lewis,
M. Baggiolini, and R. M. Steinman.
1996.
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors.
J. Exp. Med.
184:2433-2438[Abstract/Free Full Text].
|
| 31.
|
Graziosi, C.,
G. Pantaleo,
K. Gantt,
J. Fortin,
J. Demarest,
O. Cohen,
R. Sekaly, and A. Fauci.
1994.
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.
Science
265:248-252[Abstract/Free Full Text].
|
| 32.
|
Groux, H.,
G. Torpier,
D. Monte,
Y. Mouton,
A. Capron, and J. Ameisen.
1992.
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.
J. Exp. Med.
175:331-340[Abstract/Free Full Text].
|
| 33.
|
Ho, D.,
A. Neumann,
A. Perelson,
W. Chen,
J. Leonard, and M. Markowitz.
1995.
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature
373:123-126[Medline].
|
| 34.
|
Ju, S.-T.,
D. Panka,
H. Cul,
R. Ettinger,
M. El-Khatib,
D. Sherr,
B. Stanger, and A. Marshak-Rothstein.
1995.
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.
Nature
373:444-448[Medline].
|
| 35.
|
Katsikis, P. D.,
E. S. Wunderlich,
C. A. Smith,
L. A. Herzenberg, and L. A. Herzenberg.
1995.
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals.
J. Exp. Med.
181:2029-2036[Abstract/Free Full Text].
|
| 36.
|
Kelso, A.
1995.
Th1 and Th2 subsets: paradigms lost?
Immunol. Today
16:374-379[Medline].
|
| 37.
|
Kobayashi, N.,
Y. Hamamoto,
N. Yamamoto,
A. Ishii,
M. Yonehara, and S. Yonehara.
1990.
Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.
Proc. Natl. Acad. Sci. USA
87:9620-9624[Abstract/Free Full Text].
|
| 38.
|
Lapham, C. K.,
J. Ouyang,
B. Chandrasekhar,
N. Y. Nguyen,
D. S. Dimitrov, and H. Golding.
1996.
Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines.
Science
274:602-605[Abstract/Free Full Text].
|
| 39.
|
Laurent-Crawford, A.,
B. Krust,
S. Muller,
Y. Riviere,
M. Cuille,
J. Bechet,
L. Montanier, and A. Hovanessian.
1991.
The cytopathic effect of HIV is associated with apoptosis.
Virology
185:829-839[Medline].
|
| 40.
|
Levy, J.
1993.
HIV pathogenesis and long-term survival.
AIDS
7:1401-1410[Medline].
|
| 41.
|
Loetscher, P.,
M. Uguccioni,
L. Bondoli,
M. Baggiolini,
B. Moser,
C. Chizzolini, and J. Dayer.
1998.
CCR5 is characteristic of Th1 lymphocytes.
Nature
391:344-345[Medline].
|
| 42.
|
Lori, F.,
F. Veronese,
A. Del Vico,
P. Lusso,
M. Reitz, and R. Gallo.
1992.
Viral DNA carried by human immunodeficiency virus type 1 virions.
J. Virol.
66:5067-5074[Abstract/Free Full Text].
|
| 43.
|
Maggi, E.,
M. Mazzetti,
A. Ravina,
F. Annunziato,
M. De Carli,
M. Piccinni,
R. Manetti,
M. Carbonari,
A. Pesce,
G. Del Prete, and S. Romagnani.
1994.
Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells.
Science
265:244-248[Abstract/Free Full Text].
|
| 44.
|
Meyaard, L.,
R. Fouchier,
M. Brouwer,
E. Hovenkamp, and F. Miedema.
1996.
Syncytium-inducing HIV-1 replicate equally well in all types of T-helper cell clones.
AIDS
10:1598-1600[Medline].
|
| 45.
|
Meyaard, L.,
E. Hovenkamp,
I. P. M. Keet,
B. Hooibrink,
I. H. deJong,
S. A. Otto, and F. Miedema.
1996.
Single-cell analysis of IL-4 and IFN- production by T cells from HIV-infected individuals.
J. Immunol.
157:2712-2718[Abstract].
|
| 46.
|
Meyaard, L.,
S. Otto,
B. Hooibrink, and F. Miedema.
1994.
Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection.
J. Clin. Invest.
94:1947-1952.
|
| 47.
|
Meyaard, L.,
S. Otto,
R. Jonker,
M. Mijnster,
R. Keet, and F. Miedema.
1992.
Programmed death of T cells in HIV-1 infection.
Science
257:217-219[Abstract/Free Full Text].
|
| 48.
|
Mikovits, J.,
Raziuddin,
M. Gonda,
M. Ruta,
N. Lohrey,
H.-F. Kung, and F. Ruscetti.
1990.
Negative regulation of human immune deficiency virus replication in monocytes.
J. Exp. Med.
171:1705-1720[Abstract/Free Full Text].
|
| 49.
|
Mosmann, T.
1994.
Cytokine patterns during the progression to AIDS.
Science
265:193-194[Free Full Text].
|
| 50.
|
Mosmann, T.,
H. Cherwinski,
M. Bond,
M. Giedlin, and R. Coffman.
1986.
Two types of murine helper T-cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins.
J. Immunol.
136:2348-2355[Abstract].
|
| 51.
|
Mosmann, T., and R. Coffman.
1989.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol.
7:145-173[Medline].
|
| 52.
|
Murphy, W.,
Z. Tian,
O. Asai,
R. Strieter,
S. Kunkel,
D. L. Longo, and D. Taub.
1996.
Chemokines and lymphocyte activation. II. Facilitation of human cell trafficking in severe combined immunodeficiency mice.
J. Immunol.
156:2104-2111[Abstract].
|
| 53.
|
Nagata, S., and P. Golstein.
1995.
The Fas death factor.
Science
267:1449-1456[Abstract/Free Full Text].
|
| 54.
|
Openshaw, P.,
E. Murphy,
N. Hosken,
V. Maino,
K. Davis,
K. Murphy, and A. O'Garra.
1995.
Heterogeneity of intracellular cytokine synthesis at the single cell in polarized T helper 1 and T helper 2 populations.
J. Exp. Med.
182:1357-1367[Abstract/Free Full Text].
|
| 55.
|
Romagnani, S.
1991.
Human TH1 and TH2: doubt no more.
Immunol. Today
12:256-261[Medline].
|
| 56.
|
Romagnani, S.,
E. Maggi, and G. Del Prete.
1994.
An alternative view of the Th1/Th2 switch hypothesis in HIV infection.
AIDS Res. Hum. Retroviruses
10:iii-ix[Medline].
|
| 57.
|
Swain, S.
1994.
Generation and in vivo persistence of polarized TH1 and TH2 memory cells.
Immunity
1:543-552[Medline].
|
| 58.
|
Taub, D. D.,
A. Lloyd,
J. M. Wang, and J. Oppenheim.
1995.
and chemokines, p. 6.12.1-6.12.28.
In
J. Coligan, A. Kruisbeek, D. Margulies, E. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
|
| 59.
|
Terai, C.,
R. Kornbluth,
R. C. Pauza,
D. Richman, and D. Carson.
1991.
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.
J. Clin. Invest.
87:1710-1715.
|
| 60.
|
Trono, D.
1992.
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.
J. Virol.
66:4893-4900[Abstract/Free Full Text].
|
| 61.
|
Wang, J. M.,
D. McVicar,
J. Oppenheim, and D. Kelvin.
1993.
Identification of RANTES receptors on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines.
J. Exp. Med.
177:699[Abstract/Free Full Text].
|
| 62.
|
Wei, X.,
S. Ghosh,
M. Taylor,
V. Johnson,
E. Emini,
P. Deutsch,
J. Lifson,
S. Bonhoeffer,
M. Nowak,
B. Hahn,
M. Saag, and G. Shaw.
1995.
Viral dynamics in human immunodeficiency virus type 1 infection.
Nature
373:117-122[Medline].
|
| 63.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[Medline].
|
| 64.
|
Zhang, H.,
Y. Zhang,
T. Spicer,
L. Abbott,
M. Abbott, and B. Poiesz.
1993.
Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance.
AIDS Res. Hum. Retroviruses
9:1287-1296[Medline].
|
J Virol, June 1998, p. 5231-5238, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ciuffi, A., Bleiber, G., Munoz, M., Martinez, R., Loeuillet, C., Rehr, M., Fischer, M., Gunthard, H. F., Oxenius, A., Meylan, P., Bonhoeffer, S., Trono, D., Telenti, A.
(2004). Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection. J. Virol.
78: 10747-10754
[Abstract]
[Full Text]
-
Bahbouhi, B., Landay, A., Al-Harthi, L.
(2004). Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood
103: 4581-4587
[Abstract]
[Full Text]
-
Annunziato, F., Galli, G., Nappi, F., Cosmi, L., Manetti, R., Maggi, E., Ensoli, B., Romagnani, S.
(2000). Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha , and MIP-1beta. Blood
95: 1167-1174
[Abstract]
[Full Text]
-
Vicenzi, E., Bordignon, P. P., Biswas, P., Brambilla, A., Bovolenta, C., Cota, M., Sinigaglia, F., Poli, G.
(1999). Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4+ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation. J. Virol.
73: 7515-7523
[Abstract]
[Full Text]
-
Suzuki, Y., Koyanagi, Y., Tanaka, Y., Murakami, T., Misawa, N., Maeda, N., Kimura, T., Shida, H., Hoxie, J. A., O'Brien, W. A., Yamamoto, N.
(1999). Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions. J. Virol.
73: 316-324
[Abstract]
[Full Text]